RS61944B1 - Lečenje infekcije hepatitis delta virusom sa interferonom lambda - Google Patents
Lečenje infekcije hepatitis delta virusom sa interferonom lambdaInfo
- Publication number
- RS61944B1 RS61944B1 RS20210703A RSP20210703A RS61944B1 RS 61944 B1 RS61944 B1 RS 61944B1 RS 20210703 A RS20210703 A RS 20210703A RS P20210703 A RSP20210703 A RS P20210703A RS 61944 B1 RS61944 B1 RS 61944B1
- Authority
- RS
- Serbia
- Prior art keywords
- interferon lambda
- hdv
- treatment
- patient
- serum
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662297759P | 2016-02-19 | 2016-02-19 | |
| EP17753966.5A EP3416675B9 (en) | 2016-02-19 | 2017-02-17 | Treatment of hepatitis delta virus infection with interferon lambda |
| PCT/US2017/018466 WO2017143253A1 (en) | 2016-02-19 | 2017-02-17 | Treatment of hepatitis delta virus infection with interferon lambda |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS61944B1 true RS61944B1 (sr) | 2021-07-30 |
Family
ID=59625481
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20210703A RS61944B1 (sr) | 2016-02-19 | 2017-02-17 | Lečenje infekcije hepatitis delta virusom sa interferonom lambda |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US10953072B2 (enExample) |
| EP (2) | EP3416675B9 (enExample) |
| JP (3) | JP7674628B2 (enExample) |
| KR (1) | KR20180110127A (enExample) |
| CN (1) | CN108883156A (enExample) |
| CY (1) | CY1124220T1 (enExample) |
| DK (1) | DK3416675T3 (enExample) |
| ES (2) | ES2874592T3 (enExample) |
| HR (1) | HRP20210862T1 (enExample) |
| HU (1) | HUE055343T2 (enExample) |
| LT (1) | LT3416675T (enExample) |
| PL (1) | PL3416675T3 (enExample) |
| PT (1) | PT3416675T (enExample) |
| RS (1) | RS61944B1 (enExample) |
| SI (1) | SI3416675T1 (enExample) |
| SM (1) | SMT202100335T1 (enExample) |
| WO (1) | WO2017143253A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11311519B2 (en) | 2014-05-01 | 2022-04-26 | Eiger Biopharmaceuticals, Inc. | Treatment of hepatitis delta virus infection |
| DK3285768T3 (da) | 2015-04-21 | 2021-01-25 | Eiger Biopharmaceuticals Inc | Farmaceutiske sammensætninger omfattende lonafarnib og ritonavir |
| ES2874592T3 (es) | 2016-02-19 | 2021-11-05 | Eiger Biopharmaceuticals Inc | Tratamiento de la infección por el virus de la hepatitis delta con interferón lambda |
| GB201621728D0 (en) * | 2016-12-20 | 2017-02-01 | Ucb Biopharma Sprl | Methods |
| WO2020041778A1 (en) * | 2018-08-23 | 2020-02-27 | Eiger Biopharmaceuticals, Inc. | Treatment of hepatitis delta virus infection with interferon lambda |
| KR20220035365A (ko) | 2019-07-18 | 2022-03-22 | 엔요 파마 | 인터페론의 부작용을 감소시키는 방법 |
| KR20210023737A (ko) * | 2019-08-21 | 2021-03-04 | 한국과학기술원 | 신규 인터페론 람다 변이체 및 이의 제조방법 |
| AU2020368402A1 (en) * | 2019-10-16 | 2022-04-21 | Eiger Innotherapeutics, Inc. | Methods to treat hepatitis delta viral infections |
| BR112022015502A2 (pt) * | 2020-02-06 | 2022-09-27 | Eiger Biopharmaceuticals Inc | Tratamento da infecção por coronavírus com interferon lambda |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6927040B2 (en) | 2000-06-30 | 2005-08-09 | Zymogenetics, Inc. | Interferon-like protein Zcyto21 |
| US7038032B2 (en) | 2001-04-20 | 2006-05-02 | Zymogenetics, Inc. | Cytokine protein family |
| EP1575609A4 (en) | 2002-10-23 | 2010-12-15 | Zymogenetics L L C | METHOD FOR THE TREATMENT OF VIRUS INFECTIONS USING IL-28 AND IL-29 |
| WO2005023862A2 (en) | 2003-08-07 | 2005-03-17 | Zymogenetics, Inc. | Homogeneous preparations of il-28 and il-29 |
| US20050244423A1 (en) * | 2004-04-02 | 2005-11-03 | Klucher Kevin M | Methods for treating viral infection using IL-28 and IL-29 cysteine mutants |
| JP4987001B2 (ja) | 2005-07-20 | 2012-07-25 | ザイモジェネティクス リミテッド ライアビリティ カンパニー | 癌および自己免疫障害を処置するためのｉｌ２８およびｉｌ２９の短縮型システイン変異体の使用法 |
| AU2006269908A1 (en) | 2005-07-20 | 2007-01-25 | Bristol-Myers Squibb Company | IL28 and IL29 truncated cysteine mutants and antiviral methods of using same |
| WO2007041713A1 (en) | 2005-10-04 | 2007-04-12 | Zymogenetics, Inc. | Production and purification of il-29 |
| CN101610793B (zh) | 2006-09-14 | 2012-10-24 | 迈德詹尼克斯医疗以色列有限公司 | 长效药物制剂 |
| AU2009231598B2 (en) * | 2008-04-04 | 2015-03-12 | The Trustees Of The University Of Pennsylvania | Vaccines and immunotherapeutics using IL-28 and compositions and methods of using the same |
| WO2011088126A2 (en) | 2010-01-13 | 2011-07-21 | Eiger Biopharmaceuticals, Inc. | Treatment of viral infection with prenyltransferase inhibitors |
| US9579377B2 (en) * | 2011-06-14 | 2017-02-28 | Globeimmune, Inc. | Yeast-based compositions and methods for the treatment or prevention of hepatitis delta virus infection |
| WO2013028233A1 (en) * | 2011-08-25 | 2013-02-28 | Nanogen Pharmaceutical Biotechnology | Peg-interferon lambda 1 conjugates |
| US8454947B1 (en) | 2012-03-01 | 2013-06-04 | Nanogen Pharmaceutical Biotechnology | PEG-interferon lambda 1 conjugates |
| WO2014032176A1 (en) * | 2012-08-30 | 2014-03-06 | Replicor Inc. | Methods for the treatment of hepatitis b and hepatitis d infections |
| CA2890111A1 (en) * | 2012-11-02 | 2014-05-08 | Pharmacyclics, Inc. | Tec family kinase inhibitor adjuvant therapy |
| KR20240112990A (ko) | 2014-05-01 | 2024-07-19 | 아이거 바이오파마슈티컬스 인코포레이티드 | 델타 간염 바이러스 감염의 치료 |
| DK3370723T3 (da) | 2015-11-04 | 2021-01-25 | Eiger Biopharmaceuticals Inc | Behandling af hepatitis delta-virusinfektion |
| ES2874592T3 (es) | 2016-02-19 | 2021-11-05 | Eiger Biopharmaceuticals Inc | Tratamiento de la infección por el virus de la hepatitis delta con interferón lambda |
| WO2020041778A1 (en) | 2018-08-23 | 2020-02-27 | Eiger Biopharmaceuticals, Inc. | Treatment of hepatitis delta virus infection with interferon lambda |
-
2017
- 2017-02-17 ES ES17753966T patent/ES2874592T3/es active Active
- 2017-02-17 ES ES21164362T patent/ES3008560T3/es active Active
- 2017-02-17 EP EP17753966.5A patent/EP3416675B9/en active Active
- 2017-02-17 PL PL17753966T patent/PL3416675T3/pl unknown
- 2017-02-17 HR HRP20210862TT patent/HRP20210862T1/hr unknown
- 2017-02-17 DK DK17753966.5T patent/DK3416675T3/da active
- 2017-02-17 HU HUE17753966A patent/HUE055343T2/hu unknown
- 2017-02-17 WO PCT/US2017/018466 patent/WO2017143253A1/en not_active Ceased
- 2017-02-17 SM SM20210335T patent/SMT202100335T1/it unknown
- 2017-02-17 LT LTEP17753966.5T patent/LT3416675T/lt unknown
- 2017-02-17 CN CN201780020097.4A patent/CN108883156A/zh active Pending
- 2017-02-17 US US15/999,239 patent/US10953072B2/en active Active
- 2017-02-17 PT PT177539665T patent/PT3416675T/pt unknown
- 2017-02-17 SI SI201730795T patent/SI3416675T1/sl unknown
- 2017-02-17 EP EP21164362.2A patent/EP3957319B1/en active Active
- 2017-02-17 JP JP2018543599A patent/JP7674628B2/ja active Active
- 2017-02-17 KR KR1020187026586A patent/KR20180110127A/ko not_active Ceased
- 2017-02-17 RS RS20210703A patent/RS61944B1/sr unknown
-
2021
- 2021-06-10 CY CY20211100511T patent/CY1124220T1/el unknown
-
2022
- 2022-09-02 JP JP2022140259A patent/JP2022172279A/ja active Pending
-
2024
- 2024-08-01 JP JP2024125792A patent/JP2024156840A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| LT3416675T (lt) | 2021-06-25 |
| SI3416675T1 (sl) | 2021-09-30 |
| PT3416675T (pt) | 2021-06-14 |
| HUE055343T2 (hu) | 2022-05-28 |
| KR20180110127A (ko) | 2018-10-08 |
| US10953072B2 (en) | 2021-03-23 |
| EP3416675A1 (en) | 2018-12-26 |
| WO2017143253A1 (en) | 2017-08-24 |
| JP2024156840A (ja) | 2024-11-06 |
| EP3416675A4 (en) | 2020-01-08 |
| US20190111110A1 (en) | 2019-04-18 |
| US20210228686A1 (en) | 2021-07-29 |
| JP2022172279A (ja) | 2022-11-15 |
| EP3957319B1 (en) | 2024-12-04 |
| EP3416675B1 (en) | 2021-03-24 |
| SMT202100335T1 (it) | 2021-07-12 |
| JP7674628B2 (ja) | 2025-05-12 |
| ES2874592T3 (es) | 2021-11-05 |
| JP2019505553A (ja) | 2019-02-28 |
| CN108883156A (zh) | 2018-11-23 |
| CY1124220T1 (el) | 2022-05-27 |
| ES3008560T3 (en) | 2025-03-24 |
| EP3416675B9 (en) | 2021-07-14 |
| PL3416675T3 (pl) | 2021-10-11 |
| EP3957319A1 (en) | 2022-02-23 |
| DK3416675T3 (da) | 2021-06-14 |
| HRP20210862T1 (hr) | 2021-09-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RS61944B1 (sr) | Lečenje infekcije hepatitis delta virusom sa interferonom lambda | |
| JP7571008B2 (ja) | インターフェロンラムダでのデルタ肝炎ウイルス感染処置 | |
| EP2776024A1 (en) | Methods and compositions for treating hepatitis c virus | |
| Sakamoto et al. | New therapeutic approaches to hepatitis C virus | |
| EP4045034A1 (en) | Methods to treat hepatitis delta viral infections | |
| US12508297B2 (en) | Treatment of hepatitis delta virus infection with interferon lambda | |
| US20240108691A1 (en) | Treatment of hepatitis e virus infection with interferon lambda | |
| WO2024223797A1 (en) | Use of cyp3a4 inhibitors for the treatment of hepatitis d virus (hdv) infections | |
| WO2013137869A1 (en) | Combination therapy for treating hcv infection in an hcv-hiv coinfected patient population | |
| US20150164975A1 (en) | Combination therapy for treating hcv infection in an hcv-hiv coinfected patient population | |
| WO2016130122A1 (en) | Prevention of hepatitis c virus recurrence using a human hepatits c immunoglobulin preparation | |
| HK1111092A (en) | Treatment of hepatitis c in the asian population with interferon-beta |